Lansoprazole ( DrugBank: Lansoprazole )

7 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
63	特発性血小板減少性紫斑病	1
71	特発性大腿骨頭壊死症	1
85	特発性間質性肺炎	3
98	好酸球性消化管疾患	1
166	弾性線維性仮性黄色腫	2
222	一次性ネフローゼ症候群	1
299	嚢胞性線維症	1

63. 特発性血小板減少性紫斑病

臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00467571 (ClinicalTrials.gov)	March 2006	27/4/2007	Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura	Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura	Chronic Idiopathic Thrombocytopenic Purpura;Helicobacter Pylori Infection	Drug: lansoprazole, clarithromycin, amoxycillin	Mahidol University	Ramathibodi Hospital	Completed	2 Years	18 Years	Both	26	Phase 4	Thailand

71. 特発性大腿骨頭壊死症

臨床試験数 : 2 / 薬物数 : 3 - (DrugBank : 3) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 7

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000032412	2016/08/21	27/04/2018	Multicenter clinical trial: treatment effect of lansoprazole on non-traumatic osteonecrosis of the femoral head	Multicenter clinical trial: treatment effect of lansoprazole on non-traumatic osteonecrosis of the femoral head - Clinical trial for treatment effect of non-traumatic osteonecrosis of the femoral head	idiopathic osteonecrosis of the femoral head	Lansoprazole 30mg orally once a day for one year No administration	Sapporo Medical University Hospital	NULL	Complete: follow-up complete	18years-old	75years-old	Male and Female	100	Phase 2	Japan

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2071210016	11/07/2021	28/04/2021	Drug-drug interaction study of TAS-115 with lansoprazole in healthy subjects	Drug-drug interaction study of TAS-115 with lansoprazole in healthy subjects	Idiopathic pulmonary fibrosis	Day 1:TAS-115 will be orally administered. Day11-Day14:Lansoprazole will be orally administered once a day. Day 15:Lansoprazole will be orally administered and TAS-115 will be orally administered 1 hour later.	Huang Jinhong	NULL	Complete	>= 20age old	< 40age old	Male	14	Phase 1	Japan
2	NCT04965298 (ClinicalTrials.gov)	June 16, 2021	7/7/2021	Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole	The Effectiveness and Risks of Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole: a Randomised Placebo-controlled Multi-centre Clinical Trial	Idiopathic Pulmonary Fibrosis	Drug: Lansoprazole;Other: Matched placebo	Norfolk and Norwich University Hospitals NHS Foundation Trust	Norwich Clinical Trials Unit	Recruiting	40 Years	N/A	All	298	Phase 3	United Kingdom
3	EUCTR2020-000041-14-GB (EUCTR)	19/06/2020	08/07/2020	Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole	The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial - TIPAL	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Lansoprazole Product Name: Lansoprazole INN or Proposed INN: lansoprazole Other descriptive name: N/A	Norfolk and Norwich University Hospitals NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	298	Phase 3	United Kingdom

98. 好酸球性消化管疾患

臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01404832 (ClinicalTrials.gov)	October 2007	27/7/2011	The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors	The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors	Gastroesophageal Reflux Disease;Eosinophilic Esophagitis	Drug: Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms	Dallas VA Medical Center	TAP Pharmaceutical Products Inc.	Terminated	18 Years	N/A	All	102	Phase 4	United States

166. 弾性線維性仮性黄色腫

臨床試験数 : 16 / 薬物数 : 27 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 28

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04660461 (ClinicalTrials.gov)	February 4, 2020	3/12/2020	Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)	Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)	Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)	Drug: Lansoprazole 30mg;Drug: Placebo	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	NULL	Recruiting	18 Years	N/A	All	20	Phase 4	Spain
2	EUCTR2016-004021-16-ES (EUCTR)	31/10/2018	10/03/2017	Response to oral lansoprazole in patients with Pseudoxanthoma Elasticum	Response to oral lansoprazole in inorganic pyrophosphate levels in patients with Grönblad-Stranberg disease (Pseudoxanthoma Elasticum) - FIM-PXE-2016-01	Grönblad-Stranberg disease (Pseudoxanthoma Elasticum) MedDRA version: 19.1;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Trade Name: Lansoprazole INN or Proposed INN: Lansolprazole Other descriptive name: LANSOPRAZOLE	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Spain

222. 一次性ネフローゼ症候群

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00983034 (ClinicalTrials.gov)	March 2006	21/9/2009	The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy	Prospective Study of the Effects of Helicobacter Pylori Eradication on Renal Functions and Proteinuria in Patients With Membranous Nephropathy	Nephrotic Syndrome;Glomerulonephritis;Membranous Nephropathy	Drug: lansoprazole, amoxicillin, clarithromycin	Istanbul University	NULL	Completed	18 Years	70 Years	Both	70	N/A	Turkey

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00458614 (ClinicalTrials.gov)	June 2006	9/4/2007	Pharmacokinetic Study of Lansoprazole in Cystic Fibrosis	Lansoprazole Disposition in Young Children With Cystic Fibrosis	Cystic Fibrosis	Drug: Lansoprazole	Arkansas Children's Hospital Research Institute	NULL	Completed	2 Years	10 Years	Both	18	Phase 1	United States

先頭へ